PMID- 19589545
OWN - NLM
STAT- MEDLINE
DCOM- 20091221
LR  - 20211203
IS  - 1095-8673 (Electronic)
IS  - 0022-4804 (Linking)
VI  - 157
IP  - 2
DP  - 2009 Dec
TI  - Montelukast protects axial pattern rat skin flaps against ischemia/reperfusion 
      injury.
PG  - 181-6
LID - 10.1016/j.jss.2008.07.031 [doi]
AB  - BACKGROUND: Recent studies have shown that neutrophils play an important role in 
      the pathogenesis of reperfusion injury. Using an inferior epigastric artery skin 
      flap as a flap ischemia/reperfusion (I/R) injury model, we investigated whether 
      the administration of montelukast sodium, a selective reversible cysteinyl 
      leukotriene 1 (CysLT1) receptor antagonist, decreases neutrophil infiltration and 
      promotes flap survival. METHODS: Eighteen rats were used and randomly divided 
      into three groups (n=6 for each group). Group I was the sham group and did not 
      undergo ischemic insult; rather, normal saline (1 mL) was administrated 
      intraperitonealy (i.p.) 30 min before surgery and continued for 6 d. Group II 
      (control) and Group III (montelukast) underwent 12 h of ischemic insult. For 
      Group II, normal saline (1 mL) was injected i.p. 30 min before the surgery and 
      immediately before reperfusion, and this continued for 6 d. In Group III, 1 mL of 
      montelukast (10mg/kg) was injected i.p. and continued for 6 d. Malondialdehyde 
      (MDA) and glutathione (GSH) levels and myeloperoxidase (MPO) enzyme activities 
      were investigated. Histological evaluation was made to investigate the tissue 
      neutrophil count. Survival areas were assessed at 7 d postoperatively. RESULTS: 
      Group III (montelukast- treated) showed a significantly higher survival rate than 
      Group II (control) (P=0.029) but a lower survival rate than Group I (sham). 
      Histological and biochemical assays corroborated this data. CONCLUSION: This 
      study suggests that montelukast CysLT1 receptor antagonist montelukast reversed 
      I/R-induced oxidant responses and improved flap survival by inhibiting neutrophil 
      infiltration and balancing oxidant and antioxidant status.
FAU - Gideroglu, Kaan
AU  - Gideroglu K
AD  - Department of Plastic and Reconstructive Surgery, Abant Izzet Baysal University, 
      Medical Faculty, Bolu, Turkey. kaangideroglu@hotmail.com
FAU - Yilmaz, Fahrettin
AU  - Yilmaz F
FAU - Aksoy, Fadullah
AU  - Aksoy F
FAU - Bugdayci, Guler
AU  - Bugdayci G
FAU - Saglam, Ibrahim
AU  - Saglam I
FAU - Yimaz, Fahri
AU  - Yimaz F
LA  - eng
PT  - Journal Article
DEP - 20080827
PL  - United States
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
RN  - 0 (Acetates)
RN  - 0 (Cyclopropanes)
RN  - 0 (Leukotriene Antagonists)
RN  - 0 (Quinolines)
RN  - 0 (Sulfides)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - GAN16C9B8O (Glutathione)
RN  - MHM278SD3E (montelukast)
SB  - IM
MH  - Acetates/administration & dosage/*therapeutic use
MH  - Animals
MH  - Cell Movement/physiology
MH  - Cyclopropanes
MH  - Glutathione/metabolism
MH  - Graft Survival/*physiology
MH  - Injections, Intraperitoneal
MH  - Leukotriene Antagonists/administration & dosage/*therapeutic use
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Models, Animal
MH  - Neutrophils/pathology
MH  - Peroxidase/metabolism
MH  - Quinolines/administration & dosage/*therapeutic use
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reperfusion Injury/pathology/*prevention & control
MH  - Skin Transplantation/pathology/*physiology
MH  - Sulfides
MH  - Surgical Flaps/pathology/*physiology
MH  - Treatment Outcome
EDAT- 2009/07/11 09:00
MHDA- 2009/12/22 06:00
CRDT- 2009/07/11 09:00
PHST- 2008/05/01 00:00 [received]
PHST- 2008/07/09 00:00 [revised]
PHST- 2008/07/16 00:00 [accepted]
PHST- 2009/07/11 09:00 [entrez]
PHST- 2009/07/11 09:00 [pubmed]
PHST- 2009/12/22 06:00 [medline]
AID - S0022-4804(08)00495-2 [pii]
AID - 10.1016/j.jss.2008.07.031 [doi]
PST - ppublish
SO  - J Surg Res. 2009 Dec;157(2):181-6. doi: 10.1016/j.jss.2008.07.031. Epub 2008 Aug 
      27.